purpurin has been researched along with alizarin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MG; Kim, H; Lee, HW; Oh, SR; Park, D; Ryu, HW | 1 |
| Dutour, R; Poirier, D | 1 |
| Inui, K; Kanamitsu, K; Katayama, W; Kitakami, R; Mizuguchi, M; Nakagawa, S; Nakagawa, Y; Okada, T; Sawai, Y; Toyooka, N; Yokoyama, T | 1 |
1 review(s) available for purpurin and alizarin
| Article | Year |
|---|---|
Inhibitors of cytochrome P450 (CYP) 1B1.
Topics: Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Structure-Activity Relationship | 2017 |
2 other study(ies) available for purpurin and alizarin
| Article | Year |
|---|---|
Selective inhibition of monoamine oxidase A by purpurin, an anthraquinone.
Topics: Anthraquinones; Cell Line; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2017 |
Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
Topics: Amyloid Neuropathies, Familial; Anthraquinones; Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Xanthones | 2021 |